Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review.
about
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysisMechanisms of autoimmune thyroid diseases: from genetics to epigeneticsImmune checkpoint inhibitor therapy associated hypophysitisProspects of immune checkpoint modulators in the treatment of glioblastomaAdvances in understanding autoimmune pituitary disease: standardized methods for autoantibody detection.At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.Etiology of Hypopituitarism in Adult Patients: The Experience of a Single Center Database in the Serbian Population.Ipilimumab-induced autoimmune hypophysitis: a differential for sellar mass lesionsAnticytotoxic T-lymphocyte antigen-4 induced autoimmune hypophysitis: a case report and literature review.Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma.Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events.Update on hypophysitis and TTF-1 expressing sellar region masses.Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management.Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy.Low immunogenicity in non-small cell lung cancer; do new developments and novel treatments have a role?On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation.Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series.Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review.Immune checkpoint inhibitors side effects and management.Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathiesImmunotherapy approaches in the treatment of malignant brain tumors.[Treatment side effects and follow-up of malignant melanoma].[Delayed effects of oncological therapy].Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not).Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports.Immunotherapy-induced autoimmune hypophysitis.Central hypothyroidism in adults: better understanding for better care.Lymphocytic hypophysitis: modern day management with limited role for surgery.Early recognition of ipilimumab-related autoimmune hypophysitis in patients with metastatic melanoma: Case studies and recommendations for management.Nivolumab-induced hypothyroidism and selective pituitary insufficiency in a patient with lung adenocarcinoma: a case report and review of the literature.
P2860
Q26785746-06B30073-C1FA-474C-985D-3D73FB0CE576Q26827065-FD33F5C5-9D4C-4BC4-B736-AEB3E4E8ADE1Q26827140-D582F158-B4D3-4E19-9514-AA174709B938Q28081371-1F947EBB-E314-4867-9F64-94551C40188DQ33568973-BF3E121B-6093-45E4-AD68-9482AA73C2E3Q33732329-2A0552FE-0F4C-448B-9EA4-669EB88D62EEQ33862326-D70C0B82-33CE-4248-ACEA-AE1451CFF9C0Q34769437-69B1EE86-7928-4708-9A2D-83F7F8AE909CQ35074088-1EC068F4-E6D0-4E5A-8BF8-88AE6B7A9231Q36173638-99C6306D-0622-413A-9F82-FC90D08D4E99Q37091138-F066D10A-3ABB-462B-971A-51859AEA9277Q38108826-36DD6913-1055-4D5F-ADBC-6E9C07014DB8Q38166382-13BF9FE9-137A-4FC3-87E5-730B3B90F041Q38202161-38C4DF44-E099-4571-918B-246AEDB45FB2Q38366141-30CF0DB6-E4DD-4AD1-86BC-2A417500CCB3Q38391533-FE884675-4A22-4213-93BE-6631E2A7C489Q38502692-5D54D5E0-DC19-4D38-84E6-740C935A4928Q38586991-5968A996-52B6-4DD8-8520-84AA4C16EA75Q38783026-9D333A77-6550-4FD0-9A33-BA7F9F0CD7CFQ38878899-204897CF-5AB4-43E5-A0B7-6D1E5A0EEAC3Q39010566-E591F8C2-96F1-4E69-8559-E725F061AE2EQ39016790-D664FAE5-168B-49FF-A04F-598942665627Q41516358-CE002F30-8261-44EB-91F5-B8CC97B5F50FQ44239233-72C99787-F754-464D-A2E3-A95D1A1D9894Q45364903-1597215A-5A06-4CB0-BEE5-53954CCF0877Q46688417-8D0C501D-6284-474C-B475-7348F10FB2A3Q47663323-1352F26D-9FC6-423F-8BB5-EF6B6E429595Q48085347-EDD125BD-1D99-4C27-A50D-946B014D3DF7Q51751740-0E6CFF03-3192-4226-AF2E-CC37AB54FD75Q53552401-4BB3F9ED-47C9-4893-A438-30C70B99AF66Q55209741-88280415-42EE-42B6-AD4F-8F3B76C8CD31
P2860
Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Ipilimumab: a novel immunomodu ...... tis: a case report and review.
@en
type
label
Ipilimumab: a novel immunomodu ...... tis: a case report and review.
@en
altLabel
MECHANISMS IN ENDOCRINOLOGY: I ...... itis: a case report and review
@en
prefLabel
Ipilimumab: a novel immunomodu ...... tis: a case report and review.
@en
P2093
P356
P1476
Ipilimumab: a novel immunomodu ...... tis: a case report and review.
@en
P2093
Agata Juszczak
Ashley B Grossman
Avinash Gupta
Mark R Middleton
P356
10.1530/EJE-12-0167
P577
2012-04-10T00:00:00Z